Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Total Current Liabilities: 2009-2024

Historic Total Current Liabilities for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Dec 2024 value amounting to $169.3 million.

  • Madrigal Pharmaceuticals' Total Current Liabilities rose 120.08% to $391.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $391.4 million, marking a year-over-year increase of 120.08%. This contributed to the annual value of $169.3 million for FY2024, which is 42.79% up from last year.
  • Madrigal Pharmaceuticals' Total Current Liabilities amounted to $169.3 million in FY2024, which was up 42.79% from $118.5 million recorded in FY2023.
  • Over the past 5 years, Madrigal Pharmaceuticals' Total Current Liabilities peaked at $169.3 million during FY2024, and registered a low of $46.6 million during FY2020.
  • Moreover, its 3-year median value for Total Current Liabilities was $118.5 million (2023), whereas its average is $134.6 million.
  • Data for Madrigal Pharmaceuticals' Total Current Liabilities shows a peak YoY spiked of 85.26% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Madrigal Pharmaceuticals' Total Current Liabilities stood at $46.6 million in 2020, then soared by 65.04% to $76.8 million in 2021, then surged by 50.83% to $115.9 million in 2022, then rose by 2.29% to $118.5 million in 2023, then surged by 42.79% to $169.3 million in 2024.